Abstract
Environmental or occupational exposure to natural uranium can have adverse health effects, with its chemical toxicity being mainly directed towards the kidneys and skeleton. This has led to the development of chelating agents to remove uranium from the human body, including the ligand 3,4,3-LI(1,2-HOPO). We have developed a new in vitro assay to assess the efficacy of 3,4,3-LI(1,2-HOPO) in attenuating uranium-induced bone cell damage. This approach uses osteoclasts whose formation and function are altered by exposure to uranium. This assay is an interesting and effective alternative to animal methods for assessing the efficacy and safety of new uranium decorporants.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
